Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Obstructive Jaundice does not Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery

Author(s): Jin-Chao Song*, Xiao-Yan Meng*, Hua Yang, Hao Gao, Mei-Hua Cai, Ma-Zhong Zhang and Wei-Feng Yu*

Volume 19, Issue 5, 2022

Published on: 10 January, 2022

Page: [635 - 641] Pages: 7

DOI: 10.2174/1567201818666210617101630

Price: $65

Abstract

Background: Etomidate is commonly used in the induction of anesthesia. We have previously confirmed that etomidate requirements are significantly reduced in patients with obstructive jaundice and that etomidate anesthesia during Endoscopic Retrograde Cholangiopancreatography (ERCP) results in more stable hemodynamics compared to propofol. The aim of the present study is to investigate whether obstructive jaundice affects the pharmacokinetics of etomidate in patients who underwent bile duct surgery.

Methods: A total of 18 patients with obstructive jaundice and 12 non-jaundiced patients scheduled for bile duct surgery were enrolled in the study. Etomidate 0.333 mg/kg was administered by IV bolus for anesthetic induction. Arterial blood samples were drawn before, during, and up to 300 minutes after the bolus. Plasma etomidate concentrations were determined using a validated high-performance liquid chromatography-tandem mass spectrometry assay. A nonlinear mixed-effects population modeling approach was used to characterize etomidate pharmacokinetics. The covariates of age, gender, height, weight, Body Surface area (BSA), Body Mass Index (BMI), Lean Body Mass (LBM), Total Bilirubin (TBL), Alanine Aminotransferase (ALT), aspartate aminotransferase (AST), total bile acid (TBA), creatinine (CR), and blood urea nitrogen (BUN) were tested for significant effects on parameters using a multiple forward selection approach. Covariate effects were judged based on changes in the Objective Function Value (OFV).

Results: A three-compartment disposition model adequately described the pharmacokinetics of etomidate. The model was further improved when height was a covariate of total clearance [Cl1=1.30+0.0232(HT-162), ΔOFV=-7.33; P<0.01)]. The introduction of any other covariates, including bilirubin and total bile acids, did not improve the model significantly (P>0.01). For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L),Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.

Conclusion: A 3-compartment open model might best describe the concentration profile of etomidate after bolus infusion for anesthesia induction. The pharmacokinetics of etomidate did not change by the presence of obstructive jaundice.

Keywords: Population pharmacokinetics, etomidate, obstructive jaundice, nonlinear mixed-effect population model, threecompartment model, bile duct.

« Previous
Graphical Abstract

[1]
Forman, S.A. Clinical and molecular pharmacology of etomidate. Anesthesiology, 2011, 114(3), 695-707.
[http://dx.doi.org/10.1097/ALN.0b013e3181ff72b5] [PMID: 21263301]
[2]
Giese, J.L.; Stanley, T.H. Etomidate: A new intravenous anesthetic induction agent. Pharmacother. J. Human Pharmacol. Drug Ther., 1983, 3(5), 251-258.
[http://dx.doi.org/10.1002/j.1875-9114.1983.tb03266.x]
[3]
Bonnardot, J.P.; Levron, J.C.; Deslauriers, M.; Brule, M.L.; Deligne, P. [Pharmacokinetics of continuous infusion of etomidate in cirrhotic patients]. French Ann. Anesth. Resuscit., 1991, 10(5), 443-449.
[http://dx.doi.org/10.1016/S0750-7658(05)80847-0]
[4]
van Beem, H.; Manger, F.W.; van Boxtel, C.; van Bentem, N. Etomidate anaesthesia in patients with cirrhosis of the liver: Pharmacokinetic data. Anaesthesia, 1983, 38(S1)(Suppl.), 61-62.
[http://dx.doi.org/10.1111/j.1365-2044.1983.tb15181.x] [PMID: 6869758]
[5]
Song, J.C.; Sun, Y.M.; Zhang, M.Z.; Yang, L.Q.; Tao, T.Z.; Yu, W.F. The etomidate requirement is decreased in patients with obstructive jaundice. Anesth. Analg., 2011, 113(5), 1028-1032.
[http://dx.doi.org/10.1213/ANE.0b013e31822dac4a] [PMID: 21865492]
[6]
Song, J.C.; Lu, Z.J.; Jiao, Y.F.; Yang, B.; Gao, H.; Zhang, J.; Yu, W.F. Etomidate anesthesia during ERCP caused more stable haemodynamic responses compared with propofol: a randomized clinical trial. Int. J. Med. Sci., 2015, 12(7), 559-565.
[http://dx.doi.org/10.7150/ijms.11521] [PMID: 26180512]
[7]
Ribbing, J.; Jonsson, E.N. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J. Pharma. Pharmacodyn., 2004, 31(2), 109-134.
[8]
Walker, E.R.M.S. Regression modelling strategies. Technometrics, 45(2), 170-170.
[http://dx.doi.org/10.1198/tech.2003.s158]
[9]
Allen, C.; Washington, S. The role of etomidate as an anaesthetic induction agent for critically ill patients. Br. J. Hosp. Med. (Lond.), 2016, 77(5), 282-286.
[http://dx.doi.org/10.12968/hmed.2016.77.5.282] [PMID: 27166106]
[10]
De, R.G.; Popescu, D.T.; de Boer, A.G.; Smeekens, J.B.; Breimer, D.D. Pharmacokinetics of etomidate in surgical patients. Arch. Int. Pharmacodyn. Ther., 1981, 249(2), 180-188.
[11]
Van Hamme, M.J.; Ghoneim, M.M.; Ambre, J.J. Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology, 1978, 49(4), 274-277.
[http://dx.doi.org/10.1097/00000542-197810000-00010] [PMID: 697083]
[12]
Kaneda, K.; Yamashita, S.; Woo, S.; Han, T.H. Population pharmacokinetics and pharmacodynamics of brief etomidate infusion in healthy volunteers. J. Clin. Pharmacol., 2011, 51(4), 482-491.
[http://dx.doi.org/10.1177/0091270010369242] [PMID: 20498288]
[13]
Su, F.; El-Komy, M.H.; Hammer, G.B.; Frymoyer, A.; Cohane, C.A.; Drover, D.R. Population pharmacokinetics of etomidate in neonates and infants with congenital heart disease. Biopharm. Drug Dispos., 2015, 36(2), 104-114.
[http://dx.doi.org/10.1002/bdd.1924] [PMID: 25377074]
[14]
Lin, L.; Zhang, J.W.; Huang, Y.; Bai, J.; Cai, M.H.; Zhang, M.Z. Population pharmacokinetics of intravenous bolus etomidate in children over 6-months of age. Pediatr. Anesth., 2012, 24(4), 318-326.
[15]
Levron, J.C.; Assoune, P. [Pharmacokinetics of etomidate]. Ann. Fr. Anesth. Reanim., 1990, 9(2), 123-126.
[http://dx.doi.org/10.1016/S0750-7658(05)80050-4] [PMID: 2363548]
[16]
Kanda, H.; Nimura, Y.; Yasui, A.; Uematsu, T.; Kamiya, S.; Machiki, Y.; Kitagawa, Y.; Shionoya, S. Hepatic blood flow after acute biliary obstruction and drainage in conscious dogs. Hepatogastroenterology, 1996, 43(7), 235-240.
[PMID: 8682470]
[17]
Kanda, H.; Nimura, Y.; Yasui, A.; Nakano, S.; Kumada, S.; Shionoya, S. Recovery of portal blood flow after percutaneous transhepatic biliary drainage in patients with obstructive jaundice. Surg. Today, 1997, 27(2), 120.
[18]
Lin, L.; Guo, X.; Zhang, M.Z.; Qu, C.J.; Sun, Y.; Bai, J. Pharmacokinetics of dexmedetomidine in Chinese post-surgical intensive care unit patients. Acta Anaesthesiol. Scand., 2011, 55(3), 359-367.
[http://dx.doi.org/10.1111/j.1399-6576.2010.02392.x] [PMID: 21288220]
[19]
Dyck, J.B.; Maze, M.; Haack, C.; Azarnoff, D.L.; Vuorilehto, L.; Shafer, S.L. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology, 1993, 78(5), 821-828.
[http://dx.doi.org/10.1097/00000542-199305000-00003] [PMID: 8098191]

Rights & Permissions Print Cite
Article Metrics
19
1
© 2024 Bentham Science Publishers | Privacy Policy